Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cardiovascular risks under hormone replacement therapy].

E Windler1

  • 1Universitätsklinikum Hamburg-Eppendorf. Prof.Windler@t-online.de

Der Internist
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Efficacy and safety of statin therapy in old age].

Der Internist·2019
Same author

[Lipid-lowering therapy in the elderly : Who profits from which target values?]

Herz·2018
Same author

Ultrasound Diagnosis of Hepatic Steatosis as a Surrogate for Atherosclerosis.

Ultrasound international open·2016
Same author

[New therapy option for type 2 diabetes mellitus: EMPA-REG study].

Der Internist·2015
Same author

[Effects of glycemic index on cardiovascular risk factors: The OmniCarb randomized clinical trial].

Der Internist·2015
Same author

Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal.

Atherosclerosis. Supplements·2015

Hormone replacement therapy (HRT) safety needs evaluation. Low-dose estrogens may relieve menopausal symptoms in perimenopausal women with controlled cardiovascular risk, as data suggests no increased risk at this stage.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Women's Health

Background:

  • Arteriosclerotic cardiovascular disease is a leading cause of death in women.
  • Menopause is associated with increased cardiovascular risk factors like overweight and metabolic syndrome.
  • Estrogen's cardiovascular effects are complex, with in-vitro results not directly applicable in vivo.

Purpose of the Study:

  • To critically evaluate the cardiovascular safety of hormone replacement therapy (HRT).
  • To assess the applicability of existing HRT trial data to perimenopausal women.
  • To determine the appropriateness of low-dose estrogen for menopausal symptom relief in this population.

Main Methods:

  • Critical evaluation of recent cardiovascular safety trials for HRT.

Related Experiment Videos

  • Analysis of data from observational studies and intervention trials.
  • Assessment of risk factors and estrogen effects in the context of menopause.

    • Main Results:

    • Existing HRT trial data, including the Women's Health Initiative, may not be directly applicable to perimenopausal women.
    • The Women's Health Initiative data does not indicate an increased cardiovascular risk in perimenopausal women using HRT.
    • Estrogen's cardiovascular effects are diverse and context-dependent.

    Conclusions:

    • Intervention trials specifically on HRT and coronary risk in the perimenopausal period are lacking.
    • Low-dose estrogens can be considered for managing menopausal symptoms in perimenopausal women.
    • Individual cardiovascular risk assessment is crucial before initiating low-dose estrogen therapy for menopausal symptom relief.